)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
3SBio
3SBio (1530) investor relations material
3SBio H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary20 Aug, 2026
Executive summary
Revenue rose 3.9% year-over-year to RMB4,526.0 million, driven by licensing and CDMO growth despite a decline in biopharmaceutical sales.
Net profit attributable to equity shareholders fell 15.6% to RMB1,146.6 million, but adjusted net profit (excluding non-operating items) increased 26.5% to RMB1,436.3 million.
EBITDA dropped 17.7% to RMB1,508.7 million, while adjusted EBITDA rose 11.7% to RMB1,798.3 million.
The group advanced its R&D pipeline, with 25 key product candidates, several new drug approvals, and launches such as Yisaituo and NuPIAO in H1 2026.
Gross profit margin decreased to 83.8% from 85.3% year-over-year.
Financial highlights
Revenue: RMB4,526.0 million (+3.9% YoY); biopharmaceutical sales down 19.3% to RMB3,443.0 million.
Out-license income: RMB851.6 million (vs. nil YoY), mainly from Pfizer milestone payments.
CDMO revenue: RMB231.4 million (+160.9% YoY).
Gross profit: RMB3,794.6 million (+2.1% YoY); gross margin decreased to 83.8% (from 85.3%).
Basic EPS: RMB0.45 (vs. RMB0.57 YoY).
Outlook and guidance
Policy support for innovative pharmaceuticals in China is strengthening, with faster reimbursement inclusion and expanded payment capacity.
The group will focus on commercialization, R&D, and external collaboration, aiming for new product launches and pipeline advancement in H2 2026.
Continued investment in AI-assisted drug discovery and next-generation technology platforms.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from 3SBio
- Net profit attributable to owners surged 305.8% to RMB8.5 billion on record licensing revenue.1530
H2 2025 - Net profit rose 24.6% on Pfizer deal and fair value gains, despite a slight revenue decline.1530H1 2025
- Revenue and net profit rose double digits, led by TPIAO and Mandi, with robust R&D and capital strength.1530H1 2024
- Revenue up 16.5% and net profit up 34.9% year-over-year, driven by innovation and expansion.1530H2 2024
Next 3SBio earnings date
H2 202629 Mar, 2027
3SBio
Next 3SBio earnings date
H2 202629 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
3SBio Inc. is a China-based biotechnology company engaged in the research, development, manufacturing, and commercialization of biopharmaceutical products. The company focuses on therapeutic areas such as oncology, nephrology, autoimmune diseases, and dermatology. Its product portfolio includes monoclonal antibodies, recombinant proteins, and other biologic treatments. The company is headquartered in Shenyang, China, and its shares are listed on the HKEX.